CONTEXT: The associations of serum sex steroid and FSH levels with change of bone mineral density (BMD) across the complete menopausal transition are incompletely understood. OBJECTIVE: The objective of the study was to examine the associations of annual serum levels of FSH, estradiol (E2), T, and SHBG with the rates of bone loss in 3 phases: pretransmenopausal [baseline to 1 year before the final menstrual period (FMP)], transmenopausal (1 year before to 2 years after the FMP), later postmenopausal (≥ 2 years after the FMP). DESIGN: The design of the study was a repeated-measures, mixed-effects regression. SETTING: This was a community-based observational study, with a 10-year follow-up. PARTICIPANTS: A total of 720 participants of the Study of Women's Health Across the Nation Bone Study participated in the study. OUTCOME MEASURES: Annualized lumbar spine (LS) and femoral neck (FN) BMD decline was measured. RESULTS: The mean annual change in BMD was slowest in pretransmenopause (0.27%/year in FN) and fastest in transmenopause (2.16%/year in LS). In the pretransmenopausal phase, for every doubling of FSH level, LS BMD change was faster by -0.32%/year (P < .0001). In the transmenopausal phase, for every doubling of FSH level, LS BMD change was -0.35%/year faster (P < .0001); for every doubling of SHBG level, LS BMD change was -0.36%/year faster (P < .0001). In the later postmenopausal phase, for each doubling of the E2 level, the LS BMD change was slower by +0.26%/year (P = .049); for each SHBG doubling, the LS BMD change was 0.21%/year slower (P = .048). The FN associations were weaker and inconsistent. CONCLUSIONS: Higher E2 levels and lower FSH levels were associated with lower rates of LS bone loss in some but not all menopausal transition phases.
CONTEXT: The associations of serum sex steroid and FSH levels with change of bone mineral density (BMD) across the complete menopausal transition are incompletely understood. OBJECTIVE: The objective of the study was to examine the associations of annual serum levels of FSH, estradiol (E2), T, and SHBG with the rates of bone loss in 3 phases: pretransmenopausal [baseline to 1 year before the final menstrual period (FMP)], transmenopausal (1 year before to 2 years after the FMP), later postmenopausal (≥ 2 years after the FMP). DESIGN: The design of the study was a repeated-measures, mixed-effects regression. SETTING: This was a community-based observational study, with a 10-year follow-up. PARTICIPANTS: A total of 720 participants of the Study of Women's Health Across the Nation Bone Study participated in the study. OUTCOME MEASURES: Annualized lumbar spine (LS) and femoral neck (FN) BMD decline was measured. RESULTS: The mean annual change in BMD was slowest in pretransmenopause (0.27%/year in FN) and fastest in transmenopause (2.16%/year in LS). In the pretransmenopausal phase, for every doubling of FSH level, LS BMD change was faster by -0.32%/year (P < .0001). In the transmenopausal phase, for every doubling of FSH level, LS BMD change was -0.35%/year faster (P < .0001); for every doubling of SHBG level, LS BMD change was -0.36%/year faster (P < .0001). In the later postmenopausal phase, for each doubling of the E2 level, the LS BMD change was slower by +0.26%/year (P = .049); for each SHBG doubling, the LS BMD change was 0.21%/year slower (P = .048). The FN associations were weaker and inconsistent. CONCLUSIONS: Higher E2 levels and lower FSH levels were associated with lower rates of LS bone loss in some but not all menopausal transition phases.
Authors: Chevon M Rariy; Sarah J Ratcliffe; Rachel Weinstein; Shalender Bhasin; Marc R Blackman; Jane A Cauley; John Robbins; Joseph M Zmuda; Tamara B Harris; Anne R Cappola Journal: J Clin Endocrinol Metab Date: 2011-02-02 Impact factor: 5.958
Authors: A F Subar; F E Thompson; V Kipnis; D Midthune; P Hurwitz; S McNutt; A McIntosh; S Rosenfeld Journal: Am J Epidemiol Date: 2001-12-15 Impact factor: 4.897
Authors: Gail A Greendale; MaryFran Sowers; Weijuan Han; Mei-Hua Huang; Joel S Finkelstein; Carolyn J Crandall; Jennifer S Lee; Arun S Karlamangla Journal: J Bone Miner Res Date: 2012-01 Impact factor: 6.741
Authors: S K Park; S D Harlow; H Zheng; C Karvonen-Gutierrez; R C Thurston; K Ruppert; I Janssen; J F Randolph Journal: Diabet Med Date: 2017-01-04 Impact factor: 4.359
Authors: Jane A Cauley; Kristine Ruppert; Yinjuan Lian; Joel S Finkelstein; Carrie A Karvonen-Gutierrez; Sioban D Harlow; Joan C Lo; Sherri-Ann M Burnett-Bowie; Arun Karlamangla; Gail A Greendale Journal: J Clin Endocrinol Metab Date: 2019-06-01 Impact factor: 5.958
Authors: Carolyn J Crandall; Aaron Aragaki; Jane A Cauley; JoAnn E Manson; Erin LeBlanc; Robert Wallace; Jean Wactawski-Wende; Andrea LaCroix; Mary Jo O'Sullivan; Mara Vitolins; Nelson B Watts Journal: J Clin Endocrinol Metab Date: 2014-12-18 Impact factor: 5.958
Authors: Jane A Cauley; Gail A Greendale; Kristine Ruppert; Yinjuan Lian; John F Randolph; Joan C Lo; Sherri-Ann Burnett-Bowie; Joel S Finkelstein Journal: J Clin Endocrinol Metab Date: 2015-02-26 Impact factor: 5.958
Authors: Mone Zaidi; Maria I New; Harry C Blair; Alberta Zallone; Ramkumarie Baliram; Terry F Davies; Christopher Cardozo; James Iqbal; Li Sun; Clifford J Rosen; Tony Yuen Journal: J Endocrinol Date: 2018-03-19 Impact factor: 4.286
Authors: George R Bousfield; Jeffrey V May; John S Davis; James A Dias; T Rajendra Kumar Journal: Front Endocrinol (Lausanne) Date: 2018-05-09 Impact factor: 5.555